Date: May 10, 2022

Source: College of Pharmacy

Author: Zhang Zhang

Publisher: News Center

The 1.1 class of the new drug Olverembatinib (GZD824), independently developed by a team led by Prof. Ding Ke of JNU's College of Pharmacy, has been included in the Chinese Society of Clinical Oncology (CSCO) Guideline for the Diagnosis and Treatment of Hematological Diseases in 2022 and selected as one of the China's Important Medical Advances in 2021.

That program collected more than 276,000 basic documents on papers, patents and approved drugs from domestic researchers in 2021. Through quantitative analysis, expert evaluations, and comprehensive research and judgment, 77 alternative options were formulated. Finally, after recommendations from members of the Chinese Academy of Medical Sciences were reviewed by the Audit Committee and approved by the Executive Committee, the academy selected 31 important advances in 2021, among them eight in pharmacy. Olverembatinib (GZD824) was as an important advance in the field.

Olverembatinib Tablets (GZD824) were approved by the National Medical Products Administration on Nov. 25. The first prescriptions were written simultaneously in many places across the country on Dec. 31, 2021, and the drug officially applied in clinical practice. According to the global company Ascentage Pharma, sales reached 50.41 million yuan, including unaudited value added tax, by the end of February.

As the first and only approved-third generation BCR-ABL inhibitor in China, Olverembatinib (GZD824) is a breakthrough for domestic clinical practice and has potential best-in-class advantages at the global level. Since its official launch provided previously unavailable drugs for patients with drug-resistant chronic myelocytic leukemia with T315I mutation, it had significant social and clinical value.